The Center for Medical Device Development can be described as an “engineering studio,” the rapid prototyping facility provides the tools and technology to take product concepts and ideas and turn them into real life prototypes that might eventually be developed as “go-to-market” products.
Oxfordshire-based injection moulding group White Horse Plastics is extending its reach into the med-tech sector with the tooling and manufacture of luer connectors.
Pascal Medical, who has purchased and installed twelve Husky systems to create a state-of-the-art medical device production facility in Dubna, Russia, with the goal of creating an industry-leading manufacturing organization, capable of replacing foreign-import medical products with premium quality domestic production.
Germ-killing robots are being enlisted to further safeguard Vanderbilt University Medical Center (VUMC) patients from health care-associated infections. The robots will be deployed in selected inpatient areas, starting this month with the burn unit at Vanderbilt University Adult Hospital.
Torrent Pharmaceuticals said on Friday it would buy more than 120 brands from Unichem Laboratories in India and Nepal, and its manufacturing plant at Sikkim.
Researchers at ITMO University developed a new approach for obtaining non-toxic magnetic photonic crystals, expanding their applications from mainly photonics to biomedicine. Nanospheres made with the new method may be used for designing drugs to fight thrombosis and cancer.
Capsugel, now a Lonza company, a global leader in delivering high-quality, innovative dosage forms and solutions, today announced expanded clinical trial capabilities, as well as increased development and manufacturing capabilities for specialized drug products utilizing liquid-filled hard capsule (LFHC) technology, at its Edinburgh facility in Scotland.
Fosun Pharmaceutical to buy French drug distributor Tridem. The pharmaceuticals arm of Chinese conglomerate Fosun International has agreed to buy Tridem, an Africa-focused French drug distributor, for up to €63m ($73.1m).
Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender offer for 100% of the share capital of AAA subject to certain conditions. Advanced Accelerator Applications (NASDAQ:AAAP) is a radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicines including Lutathera®